(Last Updated On: July 7, 2020)

Christine Marie N. Chia-Acosta, MD, FPDS, Ricky Hipolito, MD, FPDS, Ma. Teresita G. Gabriel, MD, FPDS, Emmerson Gale S. Vista, MD, FPDS, Grace C. Manuel, RMT

Abstract

Background: Several trials on relapse rates on duration of multibacillary regimens have varying results.
Objective: To compare the relapse rate among smear-positive Leprosy patients receiving 12 blister packs of multibacillary drug therapy and 24 blister packs of multibacillary drug therapy.
Method: A review of records of smear positive Leprosy patients seen from 2002 to 2006 was done. Demographic, clinical and therapeutic data were collected. Bacteriologic index was determined from Leprosy Laboratory records.

Results: A total of 391 patients were found to have complete records for review and analysis. Relapse rate was 11.9%(28) for patients who received 12 blister packs and 1.91%(3) for patients who received 24 blister packs and the difference was found to be statistically significant (p<0.01). Distribution of relapse was statistically significant according to age (p<0.01), bacteriologic index (p<0.01) and clinical spectrum (p<0.01).

Conclusion: Relapse rates shown among smear positive leprosy patients receiving 12 blister packs vs. those receiving 24 blister packs was statistically higher which differs from previously published studies. Significant predictors were clinical spectrum, bacteriologic index of >3.5, and >4 and number of blister packs.

Key words: leprosy, relapse rate, bacteriologic index, multidrug therapy

Citation:
Chia-Acosta CMN, Hipolito R, Gabriel MTG, Vista EGS, Manuel GC. Relapse rate among smear-positive leprosy cases after 12 blister packs and 24 blister packs of multibacillary drug therapy in a tertiary hospital. Journal of the Philippine Dermatological Society 2019, 29(1), 48-55

1. Department of Health and Families. Guidelines for the Control of Leprosy in the Northern Territory, 3rd ed; 2010.1-58

2. Rea T, Modlin R. Leprosy. Fitzpatrick’s Dermatology in General Medicine. 2009; 186:1786.

3. World Health Organization. Weekly Epidemiological record. 2011; 36: 389-400.

4. Sehgal V, Joginder. Slit Skin Smear in Leprosy. Int J Derm. 1990; 29(1): 9-15.

5. Bandit C. Recent Advances in Leprosy Chemotherapy. J Trop Med Parasitol. 2006; 29:68-76.

6. World Health Organization. Guidelines for the Global Surveillance of Drug Resistance. SEA-GLP. 2009; 2: 1-32.

7. World Health Organization. Guidelines for Global Surveillance of Drug Resistance in Leprosy. 2009: 6.

8. The leprosy unit, WHO. Risk of relapse in leprosy. India J Lepr. 1995; 67:13-26.

9. World Health Organization. Chemotherapy of Leprosy. WHO Tech RepSer 847:1, 1994

10. Mitranna P, Marne RB, Varikkodan R, Bala N, Dandakeri S, Martis J.Relapses In multibacillary leprosy patients after Multidrug therapy. Lepr Rev. 2008; 79: 320-324.

11. Mitranna P, Marne RB, Varikkodan R, Bala N, Dandakeri S, Martis J. Relapses In multibacillary leprosy patients after Multidrug therapy. Lepr Rev. 2008; 79: 320-324.

12. Aveillera, JC, Vianna FR, Boechat AM, Alves LM, Madeira S. Persistence of viable bacilli in highly bacilliferous multibacillary leprosy patients after twelve doses of multidrug therapy WHO/MDT. Hansen Int. 2003; 28(1):49-52.

13. Ridley DS, Jopling WH. Classification of leprosy according to immunity: a five group system. Int J Leprosy. 1966; 34: 255–273.

14. Cellona RV. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. Int J Lepr other Mycobact Dis. 2003;71: 308-319.

 

More Articles

A randomized, double-blind, comparative study on the safety and efficacy of virgin coconut (Cocos nucifera l.) oil against 1% hydrocortisone lotion as an anti-inflammatory and antipruritic preparation for mosquito reactions

  Authors: Uy, Veronica S, MD; Gracia B. Teodosio, MD, FPDS; Ma. Teresita G. Gabriel, MD, FPDS; Mary Catherine T. Galang, MD; Mohammad Yoga A. Waskito, MD; Johannes F. Dayrit, MD, FPDS     Abstract Background: Virgin coconut oil (VCO) has been reported...

read more